Blood-based prediction and early detection of pancreatic cancer recurrence after tumor resection

Cancer Biology and Medicine 2026 Open access

Read full text
Authors: Fawaz N. Al-Shaheri, Teresa Colbatzky, Andrea S. Bauer, Chaoyang Zhang, Mohamed Saiel Saeed Alhamdani, Henning Boekhoff, Liang Xu, L. Sperling, Miriam Schenk, Christin Tjaden, Markus Wolfgang Büchler, Thilo Hackert
+3 more Natalia Giese, Jörg D. Hoheisel, Ulrike Heger
DOI: 10.20892/j.issn.2095-3941.2025.0495
Cited by: 0

Abstract

The 5-year survival rate of patients with pancreatic ductal adenocarcinoma (PDAC) is < 8%. The best therapeutic option for PDAC is tumor resection. However, most patients experience recurrence within 2 years after surgery[1][1]. Postoperative monitoring includes CT imaging and determining CA19-9

Fields of Study & Subjects

Pancreatic and Hepatic Oncology Research Cancer Genomics and Diagnostics Cholangiocarcinoma and Gallbladder Cancer Studies

Publication details

Journal / source
Cancer Biology and Medicine
Pages
1–4
Publication date
16 February 2026
Language
EN